EPP Group calls for more research to fight Ebola
The outbreak is aided by weak health systems and high levels of poverty in the largely affected areas, the EPP Group said. It is for this reason that the group asks that the European Parliament revisit and revise the European Development Fund to provide investments for a strong health care system and firm governance for all nations that have weaknesses in these areas.
"For many years, very little has been done in terms of Ebola research," Davor Ivo Stier, an EPP Group spokesman, said. "The international community, including the European Commission, stepped up efforts in the midst of the epidemic. Since it takes time for vaccines and cures to be researched, produced, tested and approved, it is necessary to be ready before another potential crisis arises. Getting to zero cases means winning the battle against Ebola. We need to aim toward winning the war and thus we appeal to the European Commission to increase efforts when it comes to Ebola vaccine research and development so we are armed with more than isolation if a similar epidemic occurs in the future."
In 2014, the European Commission spent $26.5 million for emergency vaccine research. The Innovative Medicines Initiative has called for approximately $234 million this year.